Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017)

Nancy Tich, Anthony Thibodeau, Joseph Palumbo, Thomas Dobbins, Stephen O’Quinn

Zynerba Pharmaceuticals, Devon, PA, USA; The Griesser Group, Conshohocken, PA, USA.
Disclosures

• This presentation is intended to communicate scientific and medical information about data from clinical trials involving ZYN002. ZYN002 is an experimental treatment which has not been approved by any government regulatory bodies, including the United States Food and Drug Administration (FDA), and has not been determined by the FDA to be a safe or effective treatment for any disease or condition. This presentation is not designed or intended to promote the use of ZYN002 or any other Company product in order to impact prescribing.

• Nancy Tich, Anthony Thibodeau, and Stephen O’Quinn are employees of Zynerba Pharmaceuticals. Joseph Palumbo is a former employee of Zynerba Pharmaceuticals. Thomas Dobbins is a contractor for Zynerba Pharmaceuticals.

• The trial was funded by Zynerba Pharmaceuticals.
Background

• Fragile X syndrome (FXS) is the most common monogenic cause of autism spectrum disorder (ASD)\(^1\)
• Disruption in the endocannabinoid system is one of the proposed mechanisms for the loss of synaptic plasticity and the deficits in emotional responsivity observed in FXS\(^2,3\)
• Cannabidiol acts as a negative allosteric modulator at presynaptic CB\(_1\) receptors, a 5HT\(_{1A}\) agonist, and a D\(_2\) partial agonist\(^4-6\)
• ZYN002 is a pharmaceutically produced cannabidiol transdermal gel in clinical development for the treatment of behavioral symptoms associated with FXS, ASD, and 22q11.2 deletion syndrome
• The Aberrant Behavior Checklist-Community (ABC-C) is an observer-reported outcome (ObsRO) measure that has been validated in individuals with intellectual disabilities\(^7\)
• An FXS-specific domain structure of the ABC-C (ABC-C\(_{FXS}\)), which is more representative of the FXS phenotype, has been established\(^8\) and has been used to assess changes in behaviors in trials assessing ZYN002
• ZYN002 was superior to placebo in a pre-specified ad hoc analyses in patients with either ≥90% methylation or complete methylation (100%) of their FMR1 gene in ZYN-CL-016 (CONNECT-FX), suggesting methylation may impact response to ZYN002
• ZYN2-CL-033, RECONNECT, is an ongoing Phase 3, randomized, double-blind, placebo-controlled confirmatory trial evaluating the efficacy and safety of ZYN002 over 16 weeks (NCT04977986)

Objectives

• To determine the long-term safety and efficacy of ZYN002 in patients with FXS

• To report interim analyses of data of an ongoing, open-label extension trial (OLE), ZYN2-CL-017 (NCT03802799), through February 2, 2022
Methods

• Patients ages 3 through 17 years entered the trial from:
  • **ZYN2-CL-009**, an open-label Phase 2 trial to explore the efficacy and safety of ZYN002
    • Patients who completed Part 1 of the trial and demonstrated a response to therapy were eligible to enter Part 2 of the trial and received ZYN002 for 116 weeks prior to entering ZYN2-CL-017
  • **ZYN2-CL-016 (CONNECT-FX)**, a randomized, double-blind, placebo-controlled, trial evaluating the efficacy and safety of ZYN002 over 12 weeks (NCT03614663)
    • Patients randomized into CONNECT-FX were eligible for entry into ZYN2-CL-017, as were those who were screened for CONNECT-FX but ineligible to continue in the trial
Methods (continued)

• Safety data for all enrolled patients with up to 38 months of exposure are reported

• Safety assessments included adverse events, vital signs, laboratory tests, electrocardiograms and skin assessments at the site of application
  
  • Investigator skin irritation assessments were scored as:
    
    • 0=no erythema
    • 1=minimal erythema
    • 2= moderate erythema with sharply defined borders
    • 3=intense erythema with or without edema
    • 4=intense erythema with edema and blistering/erosion

• Efficacy findings through 15 months for patients with complete (100%) methylation of their FMR1 gene who completed CONNECT-FX are reported
  
  • The primary efficacy measure was change from baseline in the Social Avoidance subscale of the ABC-\text{C}_{\text{FXS}} (ABC-\text{C}_{\text{FXS}})
ZYN2-CL-017 Trial Design and Path of Patient Entry

CONNECT-FX
(ZYN2-CL-016)
Placebo or ZYN002
250 or 500 mg/day\(^a\)
for 12 weeks
n = 230
• Completers, n = 197
• Ineligible to continue in trial, n = 33

ZYN2-CL-009
Open-label ZYN002
250 or 500 mg/day\(^a\)
for 116 weeks
n = 10

Open-Label Extension

ZYN2-CL-017
ZYN002
250 or 500 mg/day\(^a\)
N = 240\(^b\)

Outcomes

• Safety: adverse events, vital signs, laboratory tests, electrocardiograms and skin assessments
• Primary efficacy: change from baseline in Social Avoidance subscale on the ABC-C\(_{FXS}\)

\(^a\)Weight-based in 2 divided doses applied twice daily.
\(^b\)Through February 2, 2022.
## Baseline Demographics

<table>
<thead>
<tr>
<th></th>
<th>ZYN002</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>240</td>
</tr>
<tr>
<td>Mean Age, years (range)(^a)</td>
<td>9.7 (3 to 17)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>183 (76.3)</td>
</tr>
<tr>
<td>Female</td>
<td>57 (23.8)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>193 (76.3)</td>
</tr>
<tr>
<td>Asian</td>
<td>8 (3.3)</td>
</tr>
<tr>
<td>Black or African American</td>
<td>9 (3.5)</td>
</tr>
<tr>
<td>Native Hawaiian or Other Pacific Islander</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Other</td>
<td>16 (6.7)</td>
</tr>
<tr>
<td>Multiple</td>
<td>13 (5.4)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>35.1</td>
</tr>
<tr>
<td>Range (Min, Max)</td>
<td>14.6, 91.8</td>
</tr>
<tr>
<td>Baseline psychoactive medications(^b)</td>
<td>54%</td>
</tr>
</tbody>
</table>

\(^a\)Age upon entry of original trial prior to entering the OLE  
\(^b\)Did not include diphenhydramine or melatonin if used for sleep.
Safety Results

- ZYN002 was safe and well tolerated in the ZYN-CL-017 extension trial in patients with a median duration of exposure of 16 months (range 21 to 1080 days) since trial entry
  - 211 (88%) patients completed ≥6 months and 176 (73%) completed ≥12 months of treatment
  - Patients who entered from the ZYN2-CL-009 trial have a median total exposure of 62 months
- Treatment-emergent adverse events (TEAEs), whether related or unrelated to study drug, were reported by 62.9% of patients; most related to conditions commonly reported in children and adolescents
- Treatment-related AEs were reported in 12.9% of patients; the most common was application site pain (6.7%)
  - Application site pain was transient and reported as mild in 15 and moderate in 1 patient
- No clinically significant changes were observed in vital signs or electrocardiograms
  - There was no evidence of ZYN002-related changes in liver function or any other laboratories
- Investigator Skin Assessments
  - Over 90% of patients had no erythema during any month of exposure
  - Only 2 patients were reported to have moderate erythema with sharply defined borders and no patients had intense erythema
ZYN002 OLE Trial Interim Safety Data – Adverse Events
Most related to conditions commonly reported in children and adolescents

<table>
<thead>
<tr>
<th>Adverse Event Type</th>
<th>Patients (n = 240) or Events, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment Emergent Adverse Events (TEAE)a</td>
<td>62.9%</td>
</tr>
<tr>
<td>Mild-to-moderate TEAEs</td>
<td>97.6% (events)</td>
</tr>
<tr>
<td>TEAEs (≥3% of patients)</td>
<td></td>
</tr>
<tr>
<td>Upper respiratory infection</td>
<td>15.8%</td>
</tr>
<tr>
<td>Application-site pain</td>
<td>6.7%</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>5.4%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>5.0%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>5.0%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4.2%</td>
</tr>
<tr>
<td>Ear infection</td>
<td>4.2%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>3.8%</td>
</tr>
<tr>
<td>Cough</td>
<td>3.3%</td>
</tr>
<tr>
<td>Influenza</td>
<td>3.3%</td>
</tr>
<tr>
<td>Discontinuations due to TEAEs</td>
<td>2.5% (6 patients)</td>
</tr>
<tr>
<td>Serious AEs (all non-treatment-related)</td>
<td>10 events in 7 patients</td>
</tr>
<tr>
<td>Treatment-Related TEAEs</td>
<td>12.9%</td>
</tr>
<tr>
<td>Most common treatment-related AE (≥3% of patients)</td>
<td>6.7%</td>
</tr>
<tr>
<td>Application-site pain (transient; mild in 15 and moderate in 1 patient)</td>
<td></td>
</tr>
</tbody>
</table>

aTEAE, whether related or unrelated to study drug.
Efficacy Results

• Improvements were seen in ABC-C\textsubscript{FXS} Social Avoidance in the full population, with the greatest improvements being seen in patients with complete methylation of their \textit{FMR1} gene

• 156 patients (70.3\%) for whom methylation status was determined had complete methylation of their \textit{FMR1} gene

• Patients with complete methylation who completed CONNECT-FX, who also match the primary efficacy population in RECONNECT
  • Demonstrated sustained improvement in ABC-C\textsubscript{FXS} Social Avoidance from baseline
  • Achieved and maintained clinically meaningful change (\textgeq 3-point improvement) in ABC-C\textsubscript{FXS} Social Avoidance
  • Demonstrated similar improvements in ABC-C\textsubscript{FXS} Irritability subscale scores
Sustained Improvement in ABC-C_{\text{FXS}} Social Avoidance in ZYN002 and Placebo Patients who Switched to Open-Label ZYN002: Patients With Complete Methylation of FMR1\textsuperscript{a}

![Graph showing change from baseline over months for Placebo and ZYN002 patients in Double-Blind and Open-Label Extension phases.]

\textsuperscript{a}Patients matching primary efficacy population in RECONNECT
\textsuperscript{b}Least square mean ± SE; reduction equals improvement
\textsuperscript{c}ZYN2-CL-016 (CONNECT-FX)
ZYN002-Treated Patients Achieved and Maintained Clinically Meaningful Change\textsuperscript{a} in ABC-C\textsubscript{FXS} Social Avoidance: Patients with Complete Methylation of \textit{FMR1}\textsuperscript{b}

\textsuperscript{a}Meaningful change in Social Avoidance: \(\geq 3\)-point improvement from baseline; maintained for \(\geq 2\) consecutive visits

\textsuperscript{b}Patients matching primary efficacy population in RECONNECT

\textsuperscript{c}ZYN2-CL-016 (CONNECT-FX)
Conclusions

- ZYN002 is safe and well tolerated during long-term administration

- ZYN002 led to improvements in ABC-C\textsubscript{FXS} Social Avoidance in the full population, with the greatest improvements being seen in patients with complete methylation of their \textit{FMR1} gene

- Patients with complete methylation, who match the primary efficacy population in the ongoing confirmatory trial, RECONNECT, achieved and maintained clinically meaningful change in Social Avoidance, supporting design enhancements for RECONNECT

- The interim results from this open-label extension trial support the long-term safety and effectiveness of ZYN002 in children and adolescents with Fragile X syndrome, with the greatest improvements seen in those with complete methylation of their \textit{FMR1} gene
Thank you to all investigators and staff:

- Darius Adams
  Jacobs Levy Personalized Genomic Medicine & Research Program
- Elizabeth Berry-Kravis
  Rush University Medical Center
- Caroline Buchanan
  Greenwood Genetic Center
- Dejan Budimirovic
  Kennedy Krieger Institute
- Diana Cejas
  University of North Carolina
- Jonathan Cohen
  Genetics Clinics Australia
- Craig Erickson
  Cincinnati Children’s Hospital Medical Center
- Richard Frye
  Phoenix Children’s Hospital
- Randi Hagerman
  UC Davis Health System, MIND Institute
- Shivkumar Hatti
  Suburban Research Associates
- Honey Heussler
  Queensland Childrens’ Hospital
- Soo-Jeung Kim
  University of Washington
- Sarah Land
  Central States Research, LLC
- Reymundo Lozano
  Icahn School of Medicine at Mount Sinai
- Andrew Marshall
  Wellington Hospital
- Nora McNamara
  University Hospitals Cleveland Medical Center
- Raun Melmed
  Southwest Autism Research & Resource Center
- Lisa Prock
  Boston Children’s Hospital
- Natalie Silove
  Westmead Children’s Hospital
- Amy Talboy
  Emory University School of Medicine
- Nicole Tartaglia
  University of Colorado School of Medicine